With diabetes being a complex health condition, finding a cure for it naturally comes with quite a few challenges. However, scientists have recently made a huge breakthrough regarding the search for a cure by purging mice of the debilitating illness. This puts them one step closer to finally ending the suffering of thousands around the world who are living with diabetes every day.
Now, it’s worth noting that the study is still in its very early stages and there is still a lot of work to be done. However, it is encouraging to know that UT Health San Antonio researchers finally found a way to improve insulin secretion, which could potentially end insulin-dependency by diabetics, Futurism reports.
The researchers have tested their new method on lab mice that were afflicted with the disease and the rodents were cured. For one year, the subjects exhibited no symptoms to indicate that the cure did not work. Dr. Bruno Doiron, one of the researchers behind the project said as much.
“It worked perfectly,” Dr. Doiron said. “We cured mice for one year without any side effects. That’s never been seen. But it’s a mouse model, so caution is needed. We want to bring this to large animals that are closer to humans in physiology of the endocrine system.”
As a result, the researchers are now thinking about moving the cure to human trials over the next three years. That might seem like a lifetime, but it’s much closer than anyone has ever been to rid the world of diabetes.
It would seem that the obstacles won’t be much of an issue either since it would appear that the Food and Drug Administration has granted approval to similar cases in the past, News.com.au reports. If so, the world should be on track to becoming free of diabetes in the next decade or so.


Trump and Merck KGaA Partner to Slash IVF Drug Costs and Expand Fertility Coverage
Tabletop particle accelerator could transform medicine and materials science
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies
Federal Appeals Court Blocks Trump-Era Hospital Drug Rebate Plan
Neuralink Plans High-Volume Brain Implant Production and Fully Automated Surgery by 2026
CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio
Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 



